KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Work In Process: 2010-2021

Historic Work In Process for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Sep 2021 value amounting to $412.4 million.

  • Biomarin Pharmaceutical's Work In Process rose 39.01% to $412.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $412.4 million, marking a year-over-year increase of 39.01%. This contributed to the annual value of $308.3 million for FY2020, which is 11.91% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Work In Process stood at $412.4 million for Q3 2021, which was up 10.29% from $374.0 million recorded in Q2 2021.
  • Biomarin Pharmaceutical's 5-year Work In Process high stood at $412.4 million for Q3 2021, and its period low was $194.6 million during Q1 2018.
  • In the last 3 years, Biomarin Pharmaceutical's Work In Process had a median value of $350.0 million in 2019 and averaged $340.6 million.
  • Its Work In Process has fluctuated over the past 5 years, first soared by 51.46% in 2019, then fell by 11.91% in 2020.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Work In Process stood at $234.7 million in 2017, then fell by 1.54% to $231.1 million in 2018, then spiked by 51.46% to $350.0 million in 2019, then decreased by 11.91% to $308.3 million in 2020, then spiked by 39.01% to $412.4 million in 2021.
  • Its Work In Process stands at $412.4 million for Q3 2021, versus $374.0 million for Q2 2021 and $355.8 million for Q1 2021.